Ii N = 249,744 for LOS Analysis, N = 238,999 for 30-Day Mortality Analysis

Ii N = 249,744 for LOS Analysis, N = 238,999 for 30-Day Mortality Analysis

<p>Supplementary Table 1. Validation studies of CCI adaptations</p><p>Author & Study Population and data source Baseline Model CCI Adaptation Prediction of Primary Outcome Year D’Hoore Hospitalized patients with ischemic heart Age + Gender + In-hospital mortality 1993(11) disease, CHF, stroke or bacterial pneumonia Principal Diagnosis D’Hoore CCI c = 0.83 (N = 62,456), MED-ECHO database, + Hospital Care Quebec, 1989-1990 Melfi Medicare Hospitalization data from TKR Age + Gender + 30-day LOS 1995(12) surgery patients, 1985-1989 Race + Type of Mortality (N = 249,744) Arthritis Baseline c = 0.645 R2 = 0.1703 Deyo CCIc c = 0.653 R2 = 0.1743 No. of Diagnoses c = 0.733 R2 = 0.2106 Poses Hospitalization data from a prospective cohort Each parameter, In-hospital mortality 1995(13) of patients with suspected bacteremia in a e.g. age, analyzed c-statistic OR 95% CI p university hospital, Virginia, 1984-1995. (N separately (no Age 0.61 1.02 [1.00, 1.04 0.05 = 227) baseline model) Time in hospital 0.62 1.02 [1.0, 10.4] 0.03 Deyo CCI 0.64 1.2 [1.1, 1.4] 0.001 APACHE II 0.83 1.3 [1.2, 1.4] <0.0001</p><p>Ghali Hospitalization discharge abstract data from Age + Gender In-hospital mortality 1996(14) patient s with CABG surgery, Massachusetts c-statistic 95% CI R2 Health Data Consortium 1992 (N = 6791) Baseline 0.661 0.656, 0.661 0.013 Deyo CCI 0.704 0.696, 0.705 0.018</p><p>Ghali CCIinteger 0.739 0.736, 0.740 0.034 Ghali CCIcoefficents 0.757 0.755, 0.757 0.041 D’Hoore Hospitalization data from MED-ECHO, Age + Gender + D’Hoore CCI In-hospital mortality 1996(15) Quebec, hospitalized patients with ischemic Principal Diagnosis c = 0.87 heart disease, 1989-90 (N = 33,940) Roos 1997(16) Hospitalization data, Manitoba Health, Age + Gender 1-year mortality patients with CABG (n = 1,558), pacemaker Original Romano Augmented Romano surgery (n = 1,645) or hip fracture repair (n = CABG + Romano c = 0.64 c = 0.68 3,984), 1990-94. CCI PSa + Romano CCI c = 0.70 c = 0.77 HFR + Romano CCI c = 0.75 c = 0.76 Cleves Medicare Part A hospital claims data, Age + Gender 30-day 90-day 180- day mortality 1997(17) Arkansas, all admissions 1993-94 (N = NR) c-statistic c-statistic c-statistic Baseline 0.59 – 0.74 0.62 – 0.69 0.62 – 0.66 Deyo CCI 0.60 – 0.75 0.64 – 0.74 0.65 – 0.74</p><p>Deyo CCIEW 0.62 – 0.79 0.65 – 0.75 0.66 – 0.75 Romano CCI 0.61 – 0.74 0.65 – 0.75 0.66 – 0.77</p><p>Romano CCIEW 0.62 – 0.77 0.66 – 0.75 0.67 – 0.78 Librero Hospitalization data, all admissions aged ≥ Age + Gender Study-specific CCI 1-year readmission 1999(18) 16, from 12 Valencia Health Service c = 0.58 OR = 1.43 (95% CI: 1.26, 1.63) hospitals, , Spain, 1993 (N = 97,430)</p><p>Wang 2000 Medicaid, Medicare, and PAAD Age + Gender + 1-year mortality (19) hospitalization and outpatient data for all Race + SES + Year c-statistic OR 95% CI women aged ≥ 20 , , New Jersey, 1989-91 (N of Diagnosis Baseline 0.668 = 3994) Deyo CCI + Index 0.711 1.17 1.13, 1.21 Deyo CCI + Prior IP 0.695 1.22 1.16, 1.28 Deyo CCI + Prior OP 0.669 1.05 0.98, 1.12 Deyo CCI + All 0.719 1.18 1.14, 1.22 Source Klabunde Hospitalization and outpatient data, men with Age + Race + Prediction of treatment 2000(20) prostate cancer (n = 28,868) and women with Tumor stage or c-statistic OR 95% CI breast cancer (n = 14,943) from National grade + SES Study Specific CCI + 0.82 2.51* 1.90, 3.32 Cancer Institute’s SEER program linked to +Geographic Prostate Cancer 2.13** 1.66, 2.73 Medicare Part A and B claims, 1992-93 Region +Education Population Study Specific CCI + 0.74 1.88* 1.52, 2.33 Breast Cancer 1.30** 1.07, 1.56 Population Sundararajan Hospitalization data from the Victorian NR In-hospital mortality 2004(21) Admitted Episodes Dataset, all Victoria State c = 0.86 hospitals, Australia, 1997-99 (N = 400,000) Deyo CCI (ICD-9-CM) Deyo CCI (ICD-10-AM) c = 0.85 Deyo CCI (ICD-9-CM) c = 0.80 Deyo CCI (ICD-10-AM) c = 0.80 Harse Hospitalization data, patients with hip or Age + Gender + Change in SF-36 Following Surgery 2005(22) knee replacement surgery, Western Australia Surgery Type + Baseline R2 = 11.78% hospital Insurance Type + 1 year LB Romano CCI R2 = 11.78% + 1.02% Age x Gender 1 year LB Binary Romano CCI R2 = 11.78% + 1.79% Interaction Term 5 year LB Romano CCI R2 = 11.78% + 1.18 5 year LB Binary Romano CCIc R2 = 11.78% + 1.11 Holman Hospitalization data from Western Australia Age + Gender + 1-year 30-day re- LOS 2005(23) hospitals. Race + SES mortality admission Index development cohort: all hospital c-statistic c-statistic R2 admissions 1989-96 CCI 0.88 – 0.74 0.67 – 0.61 0.167 – 0.027 (N = 1,118,989) MACSS 0.90 – 0.81 0.77 – 0.64 0.332 – 0.127 Abbreviations; CCI indicates Charlson Comorbidity Index; CHF, Congestive Heart Failure; NR, Not reported; TKR, Total Knee Replacement; LOS, length of stay; PM, Pacemaker Sugery; HFR, Hip Fracture Repair; SES, Socioeconomic Status; CABG, coronary artery bypass grafting; APACHE, Acute Physiology and Chronic Health Evaluation; PAAD, pharmacy assistance for the aged and disabled; SEER, Surveillance, Epidemiology and End Results; HRQOL, Health Related Quality of Life; AMI; Acute Myocardial Infarction; TURP, transurethral resection of prostate, MDD, major depressive disorder; ICU, intensive care unit; MedPar, Medicare Provider Analysis and Review; GPRD, General Practice Research Database; ESRD, End Stage Renal Disease</p>

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    2 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us